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Carotid endarterectomy is more cost-effective than
carotid artery stenting
W. Charles Sternbergh III, MD, Gregory D. Crenshaw, MD, Hernan A. Bazan, MD, and
Taylor A. Smith, MD, New Orleans, La
Objective: Cost-effectiveness has become an important end point in comparing therapies that may be considered to have
clinical equipoise. While controversial, some feel that recent multicenter randomized controlled trials have codified
clinical equipoise between carotid endarterectomy (CEA) and carotid artery stenting (CAS).
Methods: A retrospective analysis of hospital cost and 30-day clinical outcomes was performed on patients undergoing
CEA and CAS between January 1, 2008 and September 30, 2010 at a single tertiary referral institution. Cost, not
charges, of the index hospitalization was divided into supply, labor, facility, and miscellaneous categories. All costs were
normalized to 2010 values.
Results: A total of 306 patients underwent either CEA (n  174) or CAS (n  132). Mean hospital cost for CAS was
$9426  $5776 while CEA cost was $6734  $3935 (P < .0001). This cost differential was driven by the
significantly higher direct supply costs for CAS ($5634) vs CEA ($1967) (P< .0001). The higher costs for CAS were
seen consistently in symptomatic, asymptomatic, elective, and urgent subgroups. Patients undergoing CAS who were
enrolled in a trial or registry (53.8%) incurred significantly less cost ($7779  $3525) compared to those who were
not ($11,279  $7114; P  .0004). Patients undergoing CEA trended toward a higher prevalence of being
symptomatic (44.8%) compared to CAS (34.0%; P  .058). Age was not significantly different between patients
undergoing CEA and CAS (70.2 vs 72.0, respectively; P  .36). Coronary artery disease was more common in
patients undergoing CAS (60.3% vs 39%; P .0001). The prevalence of chronic obstructive pulmonary disease, renal
failure, hypertension, and diabetes was not significantly different between cohorts. Thirty-day combined stroke/
death/myocardial infarction rate was 2.3% (4 of 174) in the CEA group and 3.8% (5 of 132) in the CAS group, P
 .5. Overall length of stay (LOS) was 2.1 days in both groups (P  .9). LOS was higher for urgent interventions
(7.3-7.5 days) and symptomatic status (2.9-3.5 days) when compared to patients treated electively (1.3-1.4 days).
Conclusions: Treatment of carotid disease with CAS was 40% more costly than CEA and did not provide better clinical
outcomes or a reduction in LOS. These trends were consistent in symptomatic, asymptomatic, urgent, and elective
subgroups At present, CAS cannot be considered a cost-effective treatment for carotid disease. ( J Vasc Surg 2012;55:
1623-8.)
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CThe primary goal for the treatment of atherosclerotic
carotid disease is the prevention of stroke. Carotid endarter-
ectomy (CEA) and carotid artery stenting (CAS) have both
demonstrated a reduction in long-term stroke risk after suc-
cessful intervention.1,2 More controversial is the periproce-
dural risk of these interventions. The Carotid Revasculariza-
tion Endarterectomy vs Stenting Trial (CREST) trial did
highlight a twofold increased risk of stroke for CAS compared
toCEA.2However, it demonstrated no significant differences
betweenCEAandCASat 30-dayswhenmyocardial infarction
(MI) was included in the composite clinical end point to
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doi:10.1016/j.jvs.2011.12.045troke and death. Although there were significantly more
trokes in the CAS group (4.1% vs 2.3%), this was counterbal-
nced by an increased risk of MI in the CEA group (2.3% vs
.1%).2 A meta-analysis of European randomized prospective
rials of CEA vs CAS in symptomatic patients strongly favored
EA as having a lower risk of stroke or death.3
In a clinical environment, where there may be clinical
quipoise (combined stroke, death, and MI) between two
herapies, the cost of delivering that intervention becomes
ncreasingly important. In the United States, the percent-
ge of gross domestic product devoted to medical care
ontinues to rise at a rate that is unsustainable. Going
orward, more efficient use of health care dollars will be
ssential. Preferential use of the most cost-effective therapy
or a given clinical problem should be part of the solution.
n an effort to further compare treatment of carotid disease,
e analyzed hospital cost and clinical outcome data of
atients undergoing CEA and CAS.
ETHODS
A retrospective analysis of hospital cost and 30-day
utcomes was performed on patients undergoing CEA and
AS between January 1, 2008 and September 30, 2010 at
single tertiary referral institution. Institutional review
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study.
The hospital patient database was queried using Cur-
rent Procedure Terminology (CPT) codes to search for
those patients who had either undergone CEA (CPT
35301) or CAS with embolic protection (CPT 37215)
during the specified period. A review of each patient’s
electronic medical chart confirmed that they had under-
gone one of the procedures during the specified time. The
patients’ charts were reviewed and information on age,
gender, procedure performed, diagnosis, symptomatology,
urgency of procedure, and 30-day outcomes was extracted.
Finally, comorbidities including history of hypertension,
diabetes, end-stage renal disease, coronary artery disease
(CAD), chronic obstructive pulmonary disease (COPD),
and congestive heart failure (CHF) were documented.
Clinical definitions. Patients were considered to be
symptomatic from their carotid disease if they had experi-
enced an ipsilateral amaurosis fugax, transient ischemic
attack (TIA), or stroke. Urgent interventions were defined
as those patients admitted with an ipsilateral ocular or
cerebral ischemic episode who were found to have signifi-
cant ipsilateral carotid disease and underwent intervention
during the index hospitalization. The 30-day clinical major
adverse event was defined as a composite of any stroke,
death, and MI. In an effort to reduce the possibility of
confounding costs not related to the carotid intervention,
patients were excluded who did not have a primary admis-
sion diagnosis of carotid disease, TIA, or stroke. In addi-
tion, those patients receiving additional surgical or inter-
ventional procedures not directly related to their carotid
procedures were excluded. Nine patients were excluded
from the analysis (all CAS) because other major procedures
were performed during the index hospitalization.
Cost methodology. Costs of the index hospitalization
were determined using the Eclipsys cost accounting system
(Eclipsys Corporation, Atlanta, Ga), an institutional finan-
cial software package that is used in many large heath care
systems. This software allows allocation of direct expenses
of the institution to a charge code level. Direct, variable,
and fixed expenses are all captured. The steps in cost
allocation are as follows: (1) transfer a copy of the general
ledger (expense information), payroll expense information,
patient demographic, and clinical and charge information
to the Eclipsys cost accounting system; (2) consolidate
expense accounts into cost components by department; (3)
allocate expenses to fixed/variable components using per-
centages; (4) allocate cost to procedure charge codes using
relative value units (RVUs).
The RVU is an allocation statistic assigned to each
expense category for every procedure charge code in order
to distribute cost equitably. This allocation statistic has no
connection with RVUs assigned byMedicare for physician-
based work services. Each procedure or item charged to a
case was assigned an RVU. Costs were then calculated
based on the relative RVU valuation. Direct and indirect
costs to the hospital were captured in the analysis. The cost
items were assigned to the following cost centers: labor txpense, supply expense, facility/equipment expense, and
iscellaneous. Once the total expense for the index hospi-
alization was calculated, it was normalized to 2010 costs
ased on the medical consumer price index. Professional
ees were not included in this cost analysis.
Statistical analysis was performed with Wilcoxon
signed rank) text, 2, and Fisher two-tailed exact test. P
alues below .05 were considered statically significant. All
ontinuous variables are presented as means  SD.
ESULTS
Three hundred fifteen patients underwent either CEA
n 174) or CAS (n 141) between January 1, 2008 and
eptember 30, 2010. Nine patients were excluded from the
rimary cohort (all receiving CAS) because they had other
ssociated procedures during the index hospitalization, in-
luding liver/kidney transplantation, coronary artery by-
ass graft surgery, other major artery intervention, coro-
ary intervention, or patent foramen ovale closure. Thus,
he final examined cohort was 306 patients who underwent
EA (n  174) or CAS (n  132).
Demographics. There was a trend towardmore symp-
omatic patients in the CEA cohort (n  78) compared to
he CAS group (n  45); 44% vs 34%, respectively, P 
058 (Table I). The frequency of urgent intervention was
imilar between the CEA group (n 22) vs the CAS group
n  14); 12.6% vs 10%, respectively, P  .72.
The mean age in the CEA and CAS groups was 70.1
.8 years and 72.0 9.7 years, respectively (P .36). Men
ccounted for 62% of the CEA group and 64% (P .36) of
he CAS group. Most patients had one or more medical
omorbidities in both cohorts (Table II). There was a trend
able I. Demographics
CEA CAS P value
otal number 174 132
ge (years) 70.1  9.8 72.0  9.7 .36
Symptomatic 44 (n  76) 34 (n  45) .058
Urgent 12.6 (n  22) 14 (n  19) .72
AS, Carotid artery stenting; CEA, carotid endarterectomy.
able II. Comparison of preoperative comorbidities in
EA vs CAS cohorts
omorbidities CEA Stenting P value
Any 88.9 94.5 .07
2 or more 61.0 71.2 .08
Diabetes 30 37 .18
ESRD 1.1 3.8 .13
HTN 84 81.1 .44
CAD 37 61.0 .0001
COPD 7.0 9.1 .48
CHF 5.2 18.2 .0003
AD, Coronary artery disease; CAS, carotid artery stenting; CEA, carotid
ndarterectomy; CHF, congestive heart failure; COPD, chronic obstructive
ulmonary disease; ESRD, end-stage renal disease; HTN, hypertension.oward a higher prevalence of medical comorbidities in the
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Volume 55, Number 6 Sternbergh et al 1625CAS cohort compared to the CEA cohort (94.5% vs 88.9%;
P  .07). There was a significantly higher prevalence of
CAD and CHF in the CAS cohort (P  .0001; Table II).
Hospital cost. The hospital cost for CAS ($9426 
$5776) was 40% greater than that of CEA ($6734 
$3935; P  .0001). The range distribution of cost is
depicted in Fig 1. This cost differential was driven by a
mean difference of $3667 in higher direct supply costs in
the CAS group ($5634  $3384) compared to the CEA
group ($1967  $1967; P  .0001). There were no
significant differences between CEA and CAS in regard to
labor or facility costs (Fig 2).
Subgroup analysis was performed comparing the cost
Fig 1. The range of distribution of total cost of carotid
individual patients.
Fig 2. Subgroup analysis of cost based on supply, labor, facility,
and other costs. Cost of supplies drives the differential in costs
between the carotid endarterectomy (CEA) and carotid artery
stenting (CAS) groups.of CEA and CAS for asymptomatic, symptomatic, elective, dnd urgent procedures (Fig 3). In all subgroup cohort
omparisons, except the urgent subgroup, there was a
onsistent statistically significant increase in cost for CAS
ompared to CEA.
Cost of CAS and CEA was also examined in relation to
atient enrollment in a trial or registry. Patients undergoing
ASwhowere enrolled in a trial or registry (53.8%; n 71)
ncurred significantly less cost ($7779 $3525) compared
o those who were not (n  61; $11,279  $7114; P 
0004). There were no significant differences in cost for
atients undergoing CEA regarding trial status (Table III).
Clinical outcome. The 30-day major adverse event
ate (stroke, death, MI) was 2.3% in the CEA group and
.8% in the CAS group (P  .5). Table IV provides the
ndividual adverse events.
Overall length of stay (LOS) was 2.1 days in both CEA
nd CAS groups (P .9). LOS in patients with symptomatic
isease (2.9-3.6 days) or who had urgent intervention (7.3-
.5 days) was much greater than patients undergoing inter-
ention electively or for asymptomatic disease (1.3-1.4 days).
n patients undergoing urgent intervention, the post-proce-
ure LOS was 3.5 (3.4) days in the CEA group and 4.3
4.0) days in the CAS group. The LOS between CEA and
AS was similar in all subgroups (Table V).
ISCUSSION
The hospital cost of CAS was demonstrated to be 40%
reater than CEA. These findings are concordant with most
rior studies examining hospital cost of CAS and CEA4-8
Table VI). The cost differential in the present study was
rterectomy (CEA) and carotid artery stenting (CAS) forendariven largely by the significant differential in direct supply
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June 20121626 Sternbergh et alcosts in the CAS group of $3667. Current hospital costs for a
carotid stent ($2100 to$2495) and embolic protectiondevice
($1594 to $1695) are approximately $3750 to $4100 com-
pared to $90 to $100 for a synthetic carotid patch used with
endarterectomy. Clearly, the cost differential of these two
therapies was due to the relatively high cost of the interven-
tional products required for CAS. There was no offsetting
savings in facility or labors costs for the CAS patients as the
LOS was similar between the two treatment groups.
This is the first carotid study to examine the effect of
symptomatic status and urgency of treatment on hospital
cost. Patients with urgent intervention incurred costs much
greater in both groups than those who were treated elec-
tively. This cost differential was driven by the much greater
LOS for urgent cases (7.3-7.5 days) compared with elective
cases (1.3-1.4 days). Additional cost for diagnostic imaging
in these cases also likely contributed. Patients being treated
for symptomatic disease likewise had greater costs than
those treated for asymptomatic disease. Increased LOS in
the symptomatic groups (2.9-3.6 days) vs the asymptom-
atic group (1.3-1.4 days) certainly played a role. The rela-
tive cost trends between CAS and CEA seen in the primary
cohorts were not altered in any subgroup. CAS was consis-
Fig 3. Breakdown of total cost of carotid endarterectom
based on subgroups of asymptomatic, symptomatic, urg
Table III. Comparison of costs for patients based on
enrollment in trial registries
CEA and CAS patients enrolled in trials vs not enrolled
Enrolled Not enrolled P value
CEA cohorts 4 170
Mean costs 5444  552 6765  305 .51
CAS cohorts 71 61
Mean costs 7779  3525 11,279  7114 .0004
CAS, Carotid artery stenting; CEA, carotid endarterectomy.tently more costly in each subgroup. AIn an environment of unsustainable escalations of
ealth care costs, profound changes in the delivery and
eimbursement of US health care are coming. The specter
f decreasing reimbursements to hospitals and providers is
ncreasing pressure to deliver more cost-efficient care.
omparative-effectiveness research has been federally man-
ated. Promoting more efficient use of health care re-
ources will include choosing the most cost-efficient ther-
pies.
The present study did not demonstrate an improve-
ent in clinical outcome with the more costly treatment
CAS), nor did it decrease LOS. Based on these data, CAS
annot be considered routinely cost-effective.
Are there subgroups that are more safely treated with
AS, thus justifying its cost premium? Most reasoned
eople would say “yes,” but there is considerable contro-
ersy as to defining that patient cohort. The only random-
zed study to date that has suggested better clinical out-
ome with CAS compared to CEA is the Stenting and
ngioplasty with Protection in Patients at High Risk for
ndarterectomy (SAPPHIRE).9 This study was the driver
n gaining Center for Medicare/Medicaid Services10 reim-
ursement for symptomatic patients felt to be “high-risk”
or CEA. Indeed, this is the cohort in which there is
roadest agreement for preferential use of CAS.
The underappreciated reality of SAPPHIRE was that
70% of patients treated were asymptomatic, and their 30-
ay and 1-year clinical outcomes for CEA and CAS were
istinctlyworse than the natural history of the disease. Patients
ith asymptomatic disease undergoing CAS in SAPPHIRE
ad a 9.9% risk of stroke, death, orMI at 1 year.9 In this same
atient cohort, the 3-year risk of ipsilateral stroke was 10.3%
3.4%/year).11 The yearly risk of stroke in patients with
symptomatic60% carotid stenosis was demonstrated to be
.2% to 2.4% in the medical arms of the Asymptomatic Ca-
otid Atherosclerosis Study (ACAS),12 the Veterans Affairs
A) vs carotid artery stenting (CAS). Comparisons of cost
nd elective cohorts.y (CEsymptomatic Cooperative Study Group,13 and Asymptom-
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currently because of improved medical therapy. Although
these trials did not include surgically “high risk” patients, such
a designation has never been shown to also translate into a
higher potential risk of stroke. Finally, the ACAS trial demon-
strated that patients needed to live 5 years before achieving a
statistically significant benefit from intervention, even with a
very low 30-day death/stroke rate of 2.2%. The projected risk
of death at 5 years in patients undergoing CAS in SAPPHIRE
was 28%.11
Based on these data from SAPPHIRE and ACAS, most
patients with major comorbidities that portend a poor 5-year
life expectancy should not have CEA or CAS for asymptom-
atic disease. Medical treatment is likely the best clinical treat-
ment for most “high risk” asymptomatic patients with carotid
artery disease. It is certainly the most cost-effective.
The present study represents a “real world” cost anal-
ysis of CEA and CAS performed at a single tertiary referral
center with significant expertise and experience in both
therapies. Whereas a small number of patients were part of
randomized prospective trials (CREST, ACT-1), most
treatment decisions were made by the intervening vascular
Table IV. Thirty-day major adverse event rate (stroke, dea
Comparison of stroke, dea
CVA MI
CEA, n  174 0.5% (1) 1.1% (2)
CAS, n  132 2.2% (3) 0.7 (1)
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CVA, cardiova
Table V. Comparison of length of stay between the CEA
Comparison of cost to
No. of patients
CAS CEA
Entire cohort 132 174
Symptomatic 45 76
Asymptomatic 87 98
Elective 118 152
Urgent 14 22
CAS, Carotid artery stenting; CEA, carotid endarterectomy.
Table VI. Hospital costs for CAS vs CEA
Author Year No. CEA N
Sternbergh et al 2012 174
Maud et al4 2010 167
Janssen et al5 2008 NA
Pawaskar et al6 2007 31
Park et al7 2006 48
Ecker et al8 2004 391
CAS, Carotid artery stenting; CEA, carotid endarterectomy; NA, not applicsurgeon or interventional cardiologist. Selection bias is a wlear concern and could confound attempts to compare the
reatment groups. In an attempt to decrease this possibility,
e excluded patients who had other major procedures
uring the index hospitalization, or who were not admitted
rimarily because of TIA, stroke, or carotid disease.
Did the treatment groups have disparate demographics
r clinical presentation? Patients undergoing CEA were
ore likely to have symptomatic disease when compared
ith those undergoingCAS. As symptomatic status is a very
trong risk factor for periprocedural stroke, this difference
ould suggest that the CEA group was at higher risk of a
oor outcome, potentially biasing the results against CEA.
onversely, in the CAS group, there was a higher preva-
ence of CAD and CHF, suggesting that the group had a
igher potential cardiac morbidity, potentially biasing the
esults against CAS. Patient age and other medical comor-
idities were similar between treatment groups.
A novel finding of this study was that CAS patients en-
olled in a trial or registry had costs that were significantly less
han thosewhowere treatedwithCASoutside of a trial. These
ata refute the notion that the differential in cost between
EA and CAS is due, in part, to additional costs associated
I)
I, and composite events
Death Combination P value
0.5% (1) 2.3% (4) .5
0.7 (1) 3.8% (5)
accident; MI, myocardial infarction.
CAS groups
of stay for subgroups
Length of stay (days)
P valuesCAS CEA
2.1  3.0 2.1  2.0 .8
3.6  3.6 2.9  3.3 .8
1.3  0.9 1.4  1.2 .8
1.4  1.2 1.3  1.0 .8
7.3  3.5 7.1  3.5 .8
AS CAS cost CEA cost % Difference
$9426 $6734 40.0
$12,782 $8916 43.4
€5400 €4012 34.6
$8219 $3765 118.3
$17,402 $12,112 43.7
$10,628 $10,148 4.8th, M
th, Mand
lengtho. C
132
167
NA
31
46
45ith protocol-mandated imaging and testing for trial patients.
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patients treated outside of a trial or clinical registry. Recent
data from Yeh et al15 have suggested that the clinical out-
comes generated in post-trial CAS registries are actually better
than “real world” outcomes. Accordingly, results from CAS
postmarket registries should be extrapolated with caution.15
The reasons for the higher costs and poorer outcomes in the
nontrial/registry CAS patients are speculative. Could these
CAS patients represent the most “high-risk” subgroup? If so,
they are also more costly to treat.
Limitations. The retrospective nature of this study cre-
ates potential selection bias issues inherent in any nonrandom-
ized study. In an effort tominimize these issues, patients were
excluded who had other major procedures during the index
hospitalization. The demographics of the treatment groups
had some differences that had the potential to bias outcomes
(and thus costs) against bothgroups.Overall, the demograph-
ics between groups were more similar that disparate. Finally,
there was an even distribution of urgent interventions be-
tween groups, which were the most costly.
Despite the robust sample size of this study, the low
adverse event rate prevented meaningful analysis of clinical
outcomes in subgroups. A type II statistical error was possible
in comparisons that did not achieve statistical significance.
Professional fees were not included in this cost analysis.
PhysicianMedicare reimbursement for CAS andCEA is iden-
tical ($1167, 2011 national average)10 so there would be no
net differential in cost by adding the provider fees. However,
there are additional anesthesia professional fees incurred with
CEA that are generally not with CAS. Professional reimburse-
ment for anesthesia varies according to length of procedure
and anesthetic type. An average Medicare reimbursement for
anesthetic services for a CEA is approximately $300 to
$425.10 Given that CAS was $2692more costly than CEA in
this study, the inclusion of professional fees would not have
altered the conclusion of the study.
CONCLUSIONS
Hospital cost of CAS was 40% greater than CEA. This
cost differential was consistently observed in all subcohorts,
including patients treated for symptomatic and asymptom-
atic disease. Clinical outcome was not statistically different,
and LOS was comparable in patients treated with CAS or
CEA. Given the significant cost premium of CAS and its
lack of improvement in clinical outcome when compared to
CEA, CAS cannot be considered routinely cost-effective in
the management of carotid artery disease.
The authors thank Mr Terry R. Bean Jr, MBA, senior
financial analyst for Ochsner Medical System, for his assis-
tance in retrieving the cost data for this work.
AUTHOR CONTRIBUTIONS
Conception and design: WS, GC
Analysis and interpretation: WS, GC, HB, TS Sata collection: WS, GC
riting the article: WS, GC
ritical revision of the article: WS, GC, HB, TS
inal approval of the article: WS, GC
tatistical analysis: WS, GC
btained funding: WS
verall responsibility: WS
EFERENCES
1. Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke
W, et al. Results of the Stent-Protected Angioplasty versus Carotid
Endarterectomy (SPACE) study to treat symptomatic stenosis at 2
years; a multinational prospective randomized trial. Lancet Neurol
2008;7:893-902.
2. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM,
Brooks W, et al. Stenting versus endarterectomy for the treatment of
carotid-artery stenosis. N Engl J Med 2010;363:11-23.
3. Luebke T, Aleksic M, Brunkwall J. Meta-analysis of randomized trials
comparing carotid endarterectomy and endovascular treatment. Eur J
Vasc Endovasc Surg 2007;34:470-9.
4. Maud A, Vázquez G, Nyman JA, Lakshminarayan K, Anderson DC,
Qureshi Al. Cost-effectiveness analysis of protected carotid artery stent
placement versus endarterectomy in high-risk patients. J Endovasc Ther
2010;17:224-9.
5. Janssen MP, de Borst GJ, Mali WP, Kappelle LJ, Moll FL, Ackerstaff
RG, et al. Carotid stenting versus carotid endarterectomy: evidence
basis and cost implications. Eur J Vasc Endovasc Surg 2008;36:258-64;
discussion 265-6.
6. Pawaskar M, Satiani B, Balkrishnan R, Starr JE. Economic evaluation of
carotid artery stenting versus carotid endarterectomy for the treatment
of carotid artery stenosis. J Am Coll Surg 2007;205:413-9.
7. Park B, Mavanur A, Dahn M, Menzoian J. Clinical outcomes and cost
comparison of carotid artery angioplasty with stenting versus carotid
endarterectomy. J Vasc Surg 2006;44:270-6.
8. Ecker RD, Brown RD Jr, Nichols DA, McClelland RL, Reinalda MS,
Piepgras DG, et al. Cost of treating high-risk symptomatic carotid artery
stenosis: stent insertion and angioplasty compared with endarterec-
tomy. J Neurosurg 2004;101:904-7.
9. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, et
al. Protected carotid-artery stenting versus endarterectomy in high-risk
patients. N Engl J Med 2004;351:1493-501.
0. Centers for Medicare & Medicaid Services. Available at: http://www.
cms.hhs.gov.
1. Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, et al.
Long-term results of carotid stenting versus endarterectomy in high-
risk patients. N Engl J Med 2008;358:1572-9.
2. [No authors listed] Endarterectomy for asymptomatic carotid artery
stenosis. Executive Committee for the Asymptomatic Carotid Athero-
sclerosis Study. Jama 1995;273:1421-8.
3. Hobson RW 2nd, Weiss DG, Fields WS, Goldstone J, Moore WS,
Towne JB, et al. Efficacy of carotid endarterectomy for asymptomatic
carotid stenosis. The Veterans Affairs Cooperative StudyGroup. NEngl
J Med 1993;328:221-7.
4. Halliday AW, Thomas DJ, Mansfield AO. The asymptomatic carotid
surgery trial (ACST). Int Angiol 1995;14:18-20.
5. Yeh RW, Kennedy K, Spertus JA, Parikh SA, Sakhuja R, Anderson HV,
et al. Do postmarketing surveillance studies represent real-world popu-
lations? A comparison of patient characteristics and outcomes after
carotid artery stenting. Circulation 2011;123:1384-90.ubmitted Oct 6, 2011; accepted Dec 19, 2011.
